Advance Program

SAN DIEGO, CA / HYBRID
JUNE 23-26, 2023
ABOUT THE MEETING
The Scientific Sessions offers researchers and health care professionals the unique opportunity to share ideas and learn about the significant advances and breakthroughs in diabetes.

Participants will receive exclusive access to more than 190 sessions and 2,000 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, expand their professional networks, and so much more. The program is categorized into eight distinct theme areas, allowing participants to focus on their specialty or expand their knowledge in other areas.

Theme Areas:
- Acute and Chronic Complications
- Behavioral Medicine, Clinical Nutrition, Education, and Exercise
- Clinical Diabetes/Therapeutics
- Epidemiology/Genetics
- Immunology/Beta-Cell Replacement
- Insulin Action/Molecular Metabolism
- Obesity/Integrated Physiology
- Islet Biology/Insulin Secretion

Don’t miss this opportunity to join your colleagues at the world’s largest and most prestigious meeting on diabetes — The American Diabetes Association’s 83rd Scientific Sessions (#ADA2023).

FORMAT AND DATES
We encourage everyone to join us June 23–26 at the San Diego Convention Center in San Diego, California.

The program will begin Friday, June 23 at 10:30 a.m., and conclude Monday, June 26 at 4:15 p.m. PT (United States Pacific Time). There are virtual meeting registration options for those who cannot join us in-person. There will be more than 75 livestreamed sessions during the meeting, and most sessions will be available on-demand 24 hours after the session occurs.

COVID-19 POLICY
- Proof of vaccination will no longer be required for participation at the Scientific Sessions.
- Masks will be optional for the Scientific Sessions.
- If there are updates to CDC guidelines or local/state mandates, ADA will notify all attendees of the updated COVID-19 policy.

LEARNING OBJECTIVES
At the conclusion of this activity attendees will be able to:
- Identify the 2023 ADA Standards of Care for classifying, diagnosing, preventing, and treating prediabetes and diabetes.
- Assess non-pharmacologic treatment options for individualizing treatment protocols for the management of hyperglycemia and hypoglycemia.
- Apply clinical decision-making tools to the assessment and treatment of the complications related to diabetes.
- Develop a more aggressive, effective, physiological, psychological, and behavioral treatment plan for patients with diabetes.
- Cite the research into current, emerging, and novel therapies for type 1 and type 2 diabetes.
- Discuss proven education strategies for increasing the impact of diabetes education with individual patients.
- Interpret the latest findings in the areas of epidemiology, genetics, immunology, beta-cell replacement, and islet biology as they relate to diabetes.

NATIONAL SCIENTIFIC & HEALTH CARE ACHIEVEMENT AWARDS
The ADA is proud to announce the recipients of the 2023 National Scientific & Health Care Achievement Awards. These awards honor those individuals who have made significant contributions through their outstanding career achievements and support in the areas of diabetes research, clinical care, and education including training, mentoring, and international impact.

The eight prestigious awards will be presented during the Scientific Sessions.

Banting Medal for Scientific Achievement
Matthew H. Tschöp, MD
Outstanding Scientific Achievement Award
Caroles Evans-Molina, MD, PhD
Albert Renold Award
Raghavan G. Mirmira, MD, PhD
Outstanding Achievement in Clinical Diabetes Award
Silva A. Arslanian, MD
Outstanding Educator in Diabetes Award
A. Enrique Caballero, MD
Outstanding Physician Clinician in Diabetes Award
Mandeep Bajaj, MBBS
Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes
Mark A. Atkinson, PhD
Kelly West Award for Outstanding Achievement in Epidemiology
Alka M. Kanaya, MD

PROFESSIONAL MEMBERSHIP AWARDS
The ADA is proud to announce the recipients of the 2023 Professional Membership Awards. These interest groups award presentations are designed to recognize and honor individuals in the diabetes scientific and medical community who have demonstrated exceptional leadership and those who have made significant research contributions and outstanding career achievements in the areas of behavioral medicine and psychology, obstetrics, and youth and reproductive health, and macromolecular complications of diabetes.

These four awards will be presented during the Scientific Sessions.

Richard R. Rubin Award (Interest Group on Behavioral Medicine & Psychology)
Deborah Young-Hyman, PhD, FTOS, FACC, CCDES
Roger Pecoraro Award (Interest Group on Foot Care)
Tze-Wei Tan, MBBS, MPH, FACS
Norbert Freinkel Award (Interest Group on Pregnancy)
Heleen R. Murphy, MB, BCH, BAQ, MD, FRACP
Edwin Bierman Award (Interest Group on Complications)
Elizabeth J. Parks, PhD

LOIS JOVANOVIC TRANSFORMATIVE WOMAN IN DIABETES AWARD
The ADA is proud to announce the recipient of the Lois Jovanovic Transformative Woman in Diabetes Award. This award recognizes a female professional in the diabetes field who has made outstanding contributions to diabetes research, clinical practice, diabetes education, public health, and/or other related disciplines.

Ann L. Albright, PhD, RDN

MEETING HIGHLIGHTS
Highly Anticipated Study Announcements
We are excited to announce that new data or updates to the following studies will be presented during the meeting:
- SURMOUNT 2 Trial Results and Potential Role of Trexipride in Treating Obesity in Type 2 Diabetes
- Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes — Results from OASM 1 and PIONEER PLUS Trials
- COORDINATE — Diabetes Study Results Symposium
- Retatrutide (LY3437943), a Novel GIP/GIP-1/Glucon Aceptor Triagonist — Obesity, NAFLD, and T2D Phase 2 Trial Results
- Is Metabolic Surgery or Lifestyle/ Medical Management of Type 2 Diabetes Optimal for Long-Term Health? Long-Term Outcomes of the ARMAILS-T2D Randomized Trial after 7–15 Years of Follow-Up

Professional Interest Groups
Professional Interest Group Discussions are held Saturday, Sunday, and Monday. Expect lively conversations, dialogue, and debate with professionals in your specialty such as islet biology, quality improvement, and technology.

Learn more and join three groups today at professional.diabetes.org/InterestGroups.

Oral Presentations
Abstracts selected for oral presentation are considered to be the best of the thousands of abstracts submitted to the Scientific Sessions. Choose from over 370 original presentations highlighting the most innovative research not found at any other meeting.

IMPORTANT DATES TO REMEMBER
Last date to register at the Advance Rate: May 11
Last date to cancel meeting registration and receive a full refund: May 11
Last date to reserve hotel rooms: June 12
Cancel hotel reservations to avoid penalty: 72 hours prior to arrival

During the Scientific Sessions, choose from over 370 original presentations submitted to the Scientific Sessions.
Corporate Symposia are satellite Corporate Symposia that will enhance your understanding of diabetes care and professional development. Every purchase supports diabetes research, advocacy, and education programs.

PROFESSIONAL MEMBERSHIP

The ADA is the pre-eminent resource for diabetes care professionals and researchers who are leading the way in patient treatment and care. Members will gain access to the latest groundbreaking research, unparalleled information, and extensive global networking opportunities.

Join today to receive:
* Free member-only webinars on current topics in diabetes—ADA webinars let you hear from diabetes experts on diabetes technology and patient care.
* Opportunities to engage and network with diabetes professionals—Your membership includes access to three Special Interest Groups and the online member forum. Foster the exchange of scientific, educational, and clinical information with colleagues around the world.
* Career development and recognition opportunities through the Women’s Interprofessional Network of the ADA (WIN ADA)—Advance your career and network with female clinicians, scientists, educators, and other health professionals in diabetes. WIN ADA will host multiple events at the Scientific Sessions.
* The annual Standards of Care—Keep the annual Standards of Medical Care in Diabetes at your fingertips. Access to the all-new Standards of Care app includes special interactive tools to take notes and bookmark important sections.
* Healthy Living—An invaluable free resource to empower patients wanting to better manage their diabetes. Featuring nutrition, recipes, fitness ideas, live cooking classes, and weight loss tips.
* Mental Health Provider Directory—Mental health care is an integral part of diabetes management. Sign up as a mental health care professional or refer your patients to our directory to seek care from mental health professionals who have expertise in diabetes care.
* Over 100 publications—Professional titles on shopdiabetes.org to enhance your patient care library.

Become a professional member at professional.diabetes.org/membership.

NEW! ADA SCHOLARS PROGRAM

Graduate students, endocrine/diabetes fellows, and early-career diabetes clinicians are invited to join the new ADA Scholars career development program.

The ADA Scholars in-person program will take place on June 22-23 at the 83rd Scientific Sessions.

Participants may be eligible for a free 1-year ADA Professional Membership and free registration for the 83rd Scientific Sessions. Apply today at professional.diabetes.org/scholars.

ADA MEETING NEWS

Don’t miss the groundbreaking science from the 83rd Scientific Sessions by visiting the meeting’s official online news source, ADAMeetingNews. Access ADAMeetingNews.org through your web browser or the Scientific Sessions Mobile App (available on iOS and Android).

REGISTRATION RATES

Full In-Person Registration with Access to Virtual through Monday, August 28, 2023. One day registration does not include virtual access.

<table>
<thead>
<tr>
<th></th>
<th>ADVANCE</th>
<th>FINAL</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>$635</td>
<td>$685</td>
<td>$595</td>
<td>$645</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$955</td>
<td>$1,005</td>
<td>$905</td>
<td>$955</td>
</tr>
<tr>
<td>Student/Fellow</td>
<td>$360</td>
<td>$380</td>
<td>$370</td>
<td>$380</td>
</tr>
<tr>
<td>One Day Registration</td>
<td>$460</td>
<td>$470</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One Day Registration – Non-Member</td>
<td></td>
<td></td>
<td>$310</td>
<td>$330</td>
</tr>
</tbody>
</table>

*To qualify for the Member rate your Medicine and Science or Health Care and Education Membership must be active through June 30, 2023 at the time of registration.

REGISTRATION CATEGORIES

One-Day Provides admittance to all sessions, including the Exhibit and Poster Hall (if open), for the selected day. You are allowed to register for only 1 One-Day Registration. One day registration does not include virtual access.

Register Online

Visit scientificsessions.diabetes.org and click on the “Registration Information” tab. Online registration is fast, easy, and secure. You will receive your confirmation letter and periodic updates via email.

Questions?

Contact the ADA Registration Support Center Monday through Friday, 9:00 a.m. to 7:00 p.m. ET (U.S. Eastern Time) at 866-290-9910 (Toll Free U.S. & Canada) or +1-415-268-2086 (International). Visit the ADA Support Center at https://ada.cmrushelp.com/s/support. Affordable Media Registration

The ADA provides complimentary access to credited media members of the media, including print, broadcast, and online media for the express purpose of gathering news and information to produce press coverage of the 83rd Scientific Sessions.

For further information regarding registration eligibility and submission requirements for your news organization, contact ScisessionsPress@diabetes.org with any questions.

Warning/Be Aware!

There are companies that are claiming to offer registration and housing services for ADA’s Scientific Sessions, which are not affiliated with ADA and do not offer any services on our behalf. You may receive emails or phone calls from these companies urging you to book hotel rooms or register. Registration and housing should only be accessed from scientificsessions.diabetes.org and reserved through ADA’s official registration and housing provider.

Convention Management Resources (CMR) and ADA International Group Department (ADA-IGD). If you do not see this logo on the website, then they are not our official provider!

If you are contacted by any agency other than CMR and ADA-IGD, please immediately notify CMR at https://ada.cmrushelp.com/s/support.
HOTEL INFORMATION
Visit scientificsessions.diabetes.org and click on the “Hotel Information” tab to reserve your room online. Reserving your room online allows you to see hotel availability in real-time and allows us to send confirmation letters instantly. It also gives us a fast and easy way to contact you via email with any changes or updates.

Hotel Reservations
Reservations are available on a first-come, first-served basis. Reserve your room early for the best selection. All hotels require a credit card guarantee. If you are unable to reserve online, a downloadable housing form is available on the Scientific Sessions website.

Support the ADA by booking your hotel room within the Scientific Sessions housing block through our official housing company, CMR. Hotel reservations can be made until June 12 based on availability. A listing of official ADA hotels, with rates and a locator map, is available at scientificsessions.diabetes.org.

International Group Organizers
If you are organizing an international group (five or more rooms) to attend the Scientific Sessions, you may reserve your hotel rooms through ADA’s International Groups Department (IGD). For more information, please visit https://www.ada-idg.com/pfGroups.aspx or email info@ada-idg.com.

Hotel Cancellations and Changes
All requests for cancellations or changes can be made by going online or by contacting ADA’s official housing company. Changes received after 12:00 p.m. PT (U.S. Pacific Time) at 866-290-9910 (Toll Free U.S. & Canada) or +1-415-268-2086 (International). Visit the ADA Support Center at https://ada.cmrushelp.com/contactsupport.

TRAVEL INFORMATION
Visit scientificsessions.diabetes.org and click on the “Travel and Transportation Information” tab for more information.

Visa Requirements
Attendees from outside the U.S. may need to apply for a visa at the American Embassy, consulate, or other visa issuing office in their country of origin. Please begin your visa application process as soon as possible, as it can take several months to receive approval.

If a letter of invitation is needed for your application, visit scientificsessions.diabetes.org and click the “Travel and Transportation Information” tab to download the letter.

PHOTOGRAPHY/SOCIAL MEDIA
Photography Allowing photographs of presentation slides at the Scientific Sessions will be at the discretion of the presenters/study author. Each presenter/study author will announce, verbally and visually on a slide at the beginning of their presentation, whether or not they approve of photos/screen captures being taken. If allowed, attendees may take photos/screen captures during presentations provided that they are for personal, noncommercial use and are not for publication or rebroadcast without the express written permission of the author.

Social Media
The ADA encourages the use of social media, when following the photo policy and within embargo restrictions, to update followers on the latest news coming from the Scientific Sessions.

Questions? Contact the ADA Registration and Housing Customer Care Center Monday through Friday, 9:00 a.m. to 7:00 p.m. PT (U.S. Eastern Time) at 888-290-9910 (Toll Free U.S. & Canada) or +1-415-268-2086 (International). Visit the ADA Support Center at https://ada.cmrushelp.com/contactsupport.

SPOTLIGHT ON SAN DIEGO
With a scene that spans from internationally renowned museums and theater companies to experimental pop-up galleries in abandoned warehouses, San Diego’s artistic landscape is one of the nation’s most diverse. San Diego is not only California’s birthplace — it is also the state’s historic soul. Visitors can forego San Diego’s North County coastline offers some of the most visually appealing scenic views in the nation.

ACCREDITATION STATEMENTS AND CONTINUING EDUCATION CREDIT
For questions regarding continuing education, please contact professionaleducation@diabetes.org.

Physicians, Nurses, and Pharmacists
In support of improving patient care, the American Diabetes Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned and by the healthcare team, and learners will receive 29.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Nurses: Pharmacist/Therapeutic change to CE credits offered up to 18.

Physicians: The Universal Activity Number is: JA0108193-0000-23-004-HD

Note for Pharmacists: Upon closing of the online evaluation, the ADA will upload the pharmacy-related continuing education information to CPE Monitor within 60 days. Per ACPE rules, the ADA does not have access nor the ability to upload credits requested after the evaluation closes.

Dietitians: The American Diabetes Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 29.5 continuing professional education (CPEUs) for completion of this program's material.

Physicians for ABIM Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 29.5 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Note: Upon submission of the online evaluation, the MOC points will be immediately transferred to the ABIM. As previously stated and per the ABIM rules, the ADA does not have access nor the ability to upload points requested after the evaluation closes.

Physicians from Europe
The European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.

Physician Associates
The American Diabetes Association has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 29.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Certified Diabetes Care and Education Specialists
The American Diabetes Association is on the NCBDE List of Approved Providers. To obtain Continuing Education Credit
Certificates of Completion/Attendance are provided to registered attendees based on completion of the online evaluation. The link to the online evaluation will be emailed to participants on June 23, 2023. The continuing education evaluation system will be available through August 21, 2023.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td>Welcome to the 83rd ADA Scientific Sessions—Keynote Address by Francis Collins, MD, PhD, and Panel Discussion (Includes Livestream)</td>
<td>Exhibition Hall</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>ADA Networking Reception</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:45 p.m.</td>
<td><strong>Oral Presentations</strong></td>
<td></td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td><em>Pathway to Stop Diabetes</em> Symposium (Includes Livestream)</td>
<td></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><strong>Symposium</strong></td>
<td></td>
</tr>
<tr>
<td>5:30 p.m.</td>
<td><strong>Oral Presentations</strong></td>
<td></td>
</tr>
<tr>
<td>6:30 p.m.</td>
<td>ADA Networking Reception</td>
<td>Exhibit Hall</td>
</tr>
</tbody>
</table>

**DAY-AT-A-GlANCE SCHEDULE**

**FRIDAY, JUNE 23, 2023**

**Acute and Chronic Complications**

**Behavioral Medicine, Clinical Nutrition, Education, and Exercise**

**Clinical Diabetes/Therapeutics**

**Epidemiology/Genetics**

**Immunology/Beta-Cell Replacement**

**Insulin Action/Molecular Metabolism**

**Obesity/Integrated Physiology**

**Islet Biology/Insulin Secretion**

---

**Exhibit Hall Hours:** 6:30 p.m.-8:30 p.m.

---

**Poster Hall Hours:** 6:30 p.m.-8:30 p.m.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. - 8:30 a.m.</td>
<td>Symposium: The Guiltless Paradigm of Physical Activity and the Foot in Persons with Diabetes (Includes Livestream) Symposium: Implementation of Guideline-Directed Medical Therapy for Cardiovascular Disease — Emerging Multidisciplinary Initiatives Panel Discussion: Behavioral Markers of Diabetes Self-Management — State of the Science and Measurement Controversies — Honoring the Legacy of Mark Payet Symposium: The Heart of the Matter — Cardiovascular Health during Pregnancy and Beyond Symposium: Overcoming Obstacles in Diabetes Management Symposium: Continuous Glucose Monitoring in Type 2 Diabetes — Are We There Yet? (Includes Livestream) Symposium: Diabetes in the Child with Obesity Symposium: ADA Diabetes Care Symposium — Social Determinants of Health — Impact on Diabetes Development and Care</td>
<td>Day-at-a-Glance Schedule — Saturday, June 24, 2023</td>
</tr>
<tr>
<td>Time</td>
<td>Acute and Chronic Complications</td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>3:15 p.m.-4:15 p.m.</td>
<td>Panel Discussion: The Future is Now — Artificial Intelligence and Diabetes Foot Disease</td>
<td>Panel Discussion: Hypoglycemia as a Quality Measure — Rationales, Challenges, and Opportunities</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>8:00 a.m.</td>
<td>Symposium: New Treatment Possibilities for Cardiovascular Residual Risk in Diabetes? (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Symposium: Diabetes Kidney Disease in Type 1 and Type 2 Diabetes — The Same Disease?</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Symposium: The NIDDK Diabetic Foot Consortium — So People with Diabetes May Stand Firm</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Symposium: Hot Topics in Nutrition — What’s the Evidence? (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Symposium: Automated Insulin Delivery Use among Pregnant Women with Type 1 Diabetes — Past, Present, and Future</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Symposium: Translating Therapy with Ultra-Long-Acting Insulins</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Panel Discussion: Updates in ADA’s Standards of Care in Diabetes — 2023 (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Symposium: Joint ADA/JDRF Symposium — Global Perspective on Population Level Type 1 Diabetes Screening and Monitoring</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Symposium: Real-World Data in Diabetes Research — Promise or Pitfall?</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>9:45 a.m.</td>
<td>President, Medicine &amp; Science Address and Banting Medal for Scientific Achievement (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Professional Interest Group: Discussion on Diabetes and Cardiovascular Disease — SGLT2 Inhibitors — Innovative Research to Form Clinical Practice (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group: Discussion on Behavioral Markers of Diabetes Self-Management — Perspectives from Clinicians and People with Diabetes</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td>Professional Interest Group: Discussion on Diabetes Self-Management Education and Support (DSMES) (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Professional Interest Group: Discussion on Eye Health</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Professional Interest Group: Discussion on Hypermagnesemia</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Professional Interest Group: Discussion on Diabetes and Cardiovascular Disease — SGLT2 Inhibitors</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Professional Interest Group: Discussion on Behavioral Markers of Diabetes Self-Management — Perspectives from Clinicians and People with Diabetes</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Professional Interest Group: Discussion on Diabetes Self-Management Education and Support (DSMES) (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Professional Interest Group: Discussion on Hypermagnesemia</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Professional Interest Group: Discussion on Diabetes and Cardiovascular Disease — SGLT2 Inhibitors</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Professional Interest Group: Discussion on Behavioral Markers of Diabetes Self-Management — Perspectives from Clinicians and People with Diabetes</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Professional Interest Group: Discussion on Diabetes Self-Management Education and Support (DSMES) (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Ask the Expert: Downloading Glucose Data Everywhere or All in One Place (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Symposium: Improving Inclusive Care in Pediatric Diabetes Clinics — ADA Youth Strategies Committee</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Symposium: Hot Topics in Nutrition — What’s the Evidence? (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Symposium: Automated Insulin Delivery Use among Pregnant Women with Type 1 Diabetes — Past, Present, and Future</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Symposium: Translating Therapy with Ultra-Long-Acting Insulins</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Panel Discussion: Updates in ADA’s Standards of Care in Diabetes — 2023 (Includes Livestream)</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Symposium: Joint ADA/JDRF Symposium — Global Perspective on Population Level Type 1 Diabetes Screening and Monitoring</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Symposium: Real-World Data in Diabetes Research — Promise or Pitfall?</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Oral Presentations: Hypoglycemia</td>
<td>General Poster Session</td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>Oral Presentations: Macrovacular Complications</td>
<td>General Poster Session</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Oral Presentations: Hypoglycemia</td>
<td>General Poster Session</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Oral Presentations: Macrovacular Complications</td>
<td>General Poster Session</td>
</tr>
</tbody>
</table>

**DAY-AT-A-GLANCE SCHEDULE**

**SUNDAY, JUNE 25, 2023**

**Registration Hours:** 7:30 a.m.-5:00 p.m.
**Shop Diabetes Store Hours:** 7:30 a.m.-6:30 p.m.
**Exhibit Hall Hours:** 10:00 a.m.-4:00 p.m.
**Poster Hall Hours:** 10:00 a.m.-1:00 p.m.
### DAY-AT-A-GLANCE SCHEDULE
**SUNDAY, JUNE 25, 2023 (CONTINUED)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>3:15 p.m.-</strong>&lt;br&gt;4:15 p.m.</td>
<td><strong>Acute and Chronic Complications</strong>&lt;br&gt;Oral Presentations&lt;br&gt;(Includes Livestream)&lt;br&gt;Diabetes Store Hours&lt;br&gt;Diabetic Kidney Disease&lt;br&gt;Oral Presentations &lt;br&gt;Neuropathy&lt;br&gt;Oral Presentations&lt;br&gt;Retinopathy</td>
</tr>
<tr>
<td><strong>4:30 p.m.-</strong>&lt;br&gt;6:00 p.m.</td>
<td><strong>Panel Discussion</strong>&lt;br&gt;Current Controversies in the Primary Prevention of Diabetes Macrovascular Complications&lt;br&gt;(Includes Livestream)&lt;br&gt;Symposium&lt;br&gt;Creating a World without Visual Loss from Diabetes</td>
</tr>
</tbody>
</table>

*Registration Hours: 7:30 a.m.-5:00 p.m.*
*Shop Diabetes Store Hours: 7:30 a.m.-6:30 p.m.*
*Exhibit Hall Hours: 10:00 a.m.-4:00 p.m.*
*Poster Hall Hours: 7:30 a.m.-6:00 p.m.*
### DAY-AT-A-GLANCE SCHEDULE  
**MONDAY, JUNE 26, 2023**

**8:00 a.m.-9:30 a.m.**
- **Symposium**  
  8GLT2 and OGLP-1RA in Cardiovascular Disease—An Update for Clinical Practice in 2023  
  (Includes Livestream)

- **Panel Discussion**  
  Empowering the Acute Care Team to Optimize Diabetes Care and Education

- **Symposium**  
  Able-Bodied Aging—Physical Activity Considerations for Older Adults with Diabetes

- **Symposium**  
  Joint ADA/ESPD Symposium — Why Aren’t All Guidelines the Same? A Focused Review of Recommendations from ESPD 2022 and ADA 2023

- **Symposium**  
  ADA Symposium — Major Advances and Discoveries in Diabetes — The Year in Review  
  (Includes Livestream)

- **Symposium**  
  NEDDK Early Career Investigator Symposium — Behavioral and Physiological Adaptations to Optimize Glucose Control with Technology — What Is Needed to Improve Outcomes and to Overcome Access and Adoption Barriers?

- **Symposium**  
  All the Omics — What Do They Tell Us about Diabetes?

- **Symposium**  
  Engineering and Site Consideration for Cell Therapy

- **Symposium**  
  Observing Metabolism through New Lens

- **Symposium**  
  Single Cell RNAseq Revolution — Decipher Metabolism One Cell at a Time

- **Symposium**  
  Metabolic Adaptation to Weight Loss in Humans

**11:30 a.m.-12:30 p.m.**
- **ePoster Theater**  
  Hypoglycemia

- **ePoster Theater**  
  Psychosocial/Behavioral Medicine

- **Professional Interest Group**  
  Professional Interest Group  
  Professional Interest Group Discussion on Diabetes Technology  
  (Includes Livestream)

- **Professional Interest Group**  
  Professional Interest Group Discussion on Health Care Improvement — Best Practices in Implementing ADA’s Standards of Care in Diabetes  
  (Includes Livestream)

- **Professional Development**  
  Professional Development  
  Cultivating Provider Resiliency and Preventing Burnout  
  (Includes Livestream)

- **Professional Interest Group**  
  Professional Interest Group Discussion on Public Health and Epidemiology — Have We Succeeded in Type 2 Diabetes Primary Prevention? A Debate  
  (Includes Livestream)

- **Professional Interest Group**  
  Professional Interest Group Discussion on Immunology, Immunogenetics, and Transplantation — Engineering Islets and Dealing with the Immune System  
  (Includes Livestream)

- **General Poster Session**

- **Panel Discussion**  
  Joint ADA/ASN Symposium — How Do We Address the Psychosocial Determinants of Health in Diabetes and Kidney Disease?  
  (Includes Livestream)

- **Symposium**  
  What is the Best Approach to the Management of Painful Diabetic Neuropathy?

- **Symposium**  
  ADE Education Recognition Program (ERP) — Impact in Pregnancy — MOMs in Control of Diabetes of South Carolina

- **Symposium**  
  ADA Education Recognition Program — Impact in Pregnancy — MOMs in Control of Diabetes of South Carolina

- **Symposium**  
  Extending Our Reach — Using Technology and Clinical Collaborations to Improve Outcomes

- **Symposium**  
  Overcoming Barriers to Diabetes Technology

- **Symposium**  
  Rotat突然的 diabetes (3.54377943), a Novel GIP/GLP-1/Agigan Receptor Triagent — Obesity, NAFLD, and T2D Phase 2 Trial Results  
  (Includes Livestream)

- **Symposium**  
  Joint ADA/The Lancet Symposium — Racial and Gender Inequalities — An International Perspective

- **Symposium**  
  Clinical Cell Therapy for Diabetes

- **Symposium**  
  Oral Presentations — Insulin Action — Molecular Metabolism

- **Symposium**  
  Exercise and Metabolic Health — Insight from Animal Studies

- **Symposium**  
  Let’s Talk about Sex (Differences in Islet Biology)  
  (Includes Livestream)
<table>
<thead>
<tr>
<th>3:15 p.m. - 4:15 p.m.</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Beta-Cell Replacement</th>
<th>Immunology/Epidemiology/Genetics</th>
<th>Insulin Action/Epidemiology/Molecular Metabolism</th>
<th>Obesity/Integrated Physiology</th>
<th>Islet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symposium</td>
<td>Beyond Antihyperglycemic and Antihypertensive Agents for Diabetic Kidney Disease (Includes Livestream)</td>
<td>Symposium</td>
<td>Updates in Diabetes and Fasting</td>
<td>Symposium</td>
<td>Shared Decision-Making: Either Isn’t Practiced or Isn’t Working</td>
<td>Symposium</td>
<td>Is Metabolic Surgery or Lifestyle/Medical Management of Type 2 Diabetes Optimal for Long-Term Health? Long-Term Outcomes of the ARMMSS-T2D Randomized Trial after 7-15 Years of Follow-Up (Includes Livestream)</td>
<td>Symposium</td>
</tr>
</tbody>
</table>
10:30 a.m.-11:30 a.m.
Welcome to the 83rd ADA Scientific Sessions! (Includes Livestream)
Robert A. Gabbay, MD, PhD
Keynote Speaker Address
Francis S. Collins, MD, PhD
Panel Discussion
Robert A. Gabbay, MD, PhD
Francis S. Collins, MD, PhD
Griffin Rodgers, MD, MACP
William T. Cefalu, MD

11:30 a.m.-12:30 p.m.
“Pathway to Stop Diabetes” Symposium (Includes Livestream)
12:45 p.m.-1:45 p.m.
To Eat or Not to Eat? Fasted vs. Postprandial Exercise for Glycemic Management (Includes Livestream)
Normand G. Boulé, PhD
Jenna B. Gillen, PhD

2:00 p.m.-3:30 p.m.
Management of the Athlete with Diabetes (Includes Livestream)
Physiology, Metabolism, and Training Behaviors of the Competitive Athlete Living with Type 2 Diabetes
Michael Riddell, MD
Clinical Strategies to Support the Developing Athlete with Type 1 Diabetes
Lori M. Laffel, MD, MPH

4:00 p.m.-5:15 p.m.
Interactive Case Studies — AID Systems — Which Setting Would You Change? (Includes Livestream)
Introductory Lecture on Systems and Resources
Sue A. Brown, MD
Considerations When Switching between AID Devices
Alexandria Ratliff-Leewing, PhD
Therapeutic and Technological Options to Prevent Hypoglycemia in Older Adults with Diabetes

2:00 p.m.-3:30 p.m.
Real-World Hypoglycemia in Older Adults with Diabetes
Real-World Epidemiology and Diverse Impacts of Hypoglycemia in Older Adults with Diabetes

2:00 p.m.-3:30 p.m.
Remission or Bust!
Remission or Bust!
Vanita R. Aroda, MD
Sangeeta Kashyap, MD
Vanita R. Aroda, MD

3:45 p.m.-5:15 p.m.
SURMOUNT 2 — Rationale, Hypotheses, and Study Design
Juan Pablo Frias, MD
SURMOUNT 2 — Efficacy Data
W. Timothy Garvey, MD, MACE
SURMOUNT 2 — Safety Data
Naveed Sattar, MD, PhD
Putting SURMOUNT 2 Results in Context and Implications Regarding Treatment of Patients Having Both Obesity and Type 2 Diabetes
Iditco Lingvay, MD, MPH, MICS

4:00 p.m.-5:15 p.m.
Research and Development of Bacterial Insulin
Potential Role of Tirzepatide in Treating Obesity in Type 2 Diabetes—Opportunities and Challenges
Nida Haider, PhD

5:15 p.m.-6:30 p.m.
Designer Beta Cells
Introduction — Current State and Future Needs of Beta-Cell Replacement in Diabetes
M. Cristina Nostro, PhD
How Do We Manage Immunogenicity?
Audrey Parent, PhD
Designing a Cell Source for the Future
Heiko Liickert, PhD
Are There Other Cell Sources Beyond ESC and PSCG?
Qiao Zhou, PhD

6:30 p.m.-8:00 p.m.
Welcome to Exosomes — Their Role in Obesity
Introduction to Exosomes — Production and Cargo
C. Ronald Kahn, MD
Adipose Tissue Macrophage Exosomes and Atdiogenesis
Wei Ying, PhD
Adipocyte Exosomes and Metabolic Function
Philipp E. Scherer, PhD
Human Data on Exosomes
David Semenkovich, PhD
Question and Discussion Period

8:00 p.m.-10:00 p.m.
Maintaining Correct Insulin Delivery
How Do We Manage Immunogenicity?
Audrey Parent, PhD
Designing a Cell Source for the Future
Heiko Liickert, PhD
Are There Other Cell Sources Beyond ESC and PSCG?
Qiao Zhou, PhD

8:00 p.m.-10:00 p.m.
Diabetic Myopathy and Muscle Metabolism
Impact of Diabetes and Metformin on Muscle Quality and Satellite Cell Function
Jean Fanup, PhD
Sex Differences in Muscle Insulin Resistance
Nida Haider, PhD
Muscle Health and Recovery from Exercise in Type 1 Diabetes
Irena Rebaika, PhD

Question and Discussion Period

FRIDAY, JUNE 23

Overcoming Therapeutic Inertia — Leveraging the Diabetes Care Interprofessional Team (Includes Livestream)
Panel Discussion
Sandra Leal, PharmD, MPH, FAPA
Lucia Novak,MSN, ANP-BC, BCADM, CDT
Question and Discussion Period

Where Lie the Keys to Type 2 Diabetes Prevention? Population Health or Personalized Medicine? (Includes Livestream)
Population Health Approaches Personalized Medicine Approaches
Sindharan Raghavan, MD, PhD
Question and Discussion Period

Oral Presentations
2:00 p.m.-3:30 p.m.
Management of the Athlete with Diabetes (Includes Livestream)
Intervention to Improve Diabetes Distress among Adults with Type 1 Diabetes
Roy Taylor, MD
Very Low Carbohydrate Diets for Management of Type 2 Diabetes
Michael Riddell, PhD
Clinical Strategies to Support the Developing Athlete with Type 1 Diabetes
Lori M. Laffel, MD, MPH

Translating Psychosocial Care into Real-World Practice Settings (Includes Livestream)
Psychosocial and Behavioral Screening in Real-World Pediatric Type 1 Diabetes Care
Intervening to Improve Diabetes Distress among Adults with Type 1 and Type 2 Diabetes
Lawrence Fisher, PhD, ABPP
Family-Based Intervention to Support Transitioning from Pediatric to Adult Type 1 Diabetes Care
Peer-Support Models for Diabetes Management Support in Real-World Practice
Tricia S. Tang, PhD, RPysch
Question and Discussion Period

Glucagon Fest
New Glucagon Formulations
Leah M. Wilson, MD
Glucagon Use during Exercise
Rémi Rabasa-Lhoret, MD, PhD
Glucagon in a Bihormonal Bionic Pancreas System
Edward Damiano, PhD

SURMOUNT 2 Trial Results and Potential Role of Tirzepatide in Treating Obesity in Type 2 Diabetes (Includes Livestream)
Current Therapeutic Landscape for Treating Obesity in Type 2 Diabetes—Two Diseases Each Requiring Optimal Therapy
W. Timothy Garvey, MD, MACE
Tirzepatide and The Rationale, Pharmacology, and Mechanism of Multifunctional Peptides
Mathias H. Tschoip, MD
8:00 a.m.-9:30 a.m.

- The Goldilocks Paradox of Physical Activity and the Foot in Persons with Diabetes (Includes Livestream)
- Emerging Multidisciplinary Initiatives Where We Fall Short — Current Gaps in the Management of Cardiometabolic Disease
- Training at Intersections — The Cardiometabolic Fellowship
- One Stop Shop — The Cardiometabolic Clinic
- Role of Continuous Glucose Monitoring in Non-Insulin Requiring Type 2 Diabetes
- Is CGM or RCGM in Insulin-Treated Type 2 Diabetes
- Diabetes in the Child with Obesity
- Behavioral Markers of Diabetes Self-Management — State of the Science and Measurement Controversies — Honoring the Legacy of Mark Peyrot
- Measuring Self-Management Behaviors via Self-Report and (or vs.) Technology
- Measuring Self-Management Behaviors via Ecological Momentary Assessment
- Measuring Sleep in Diabetes
- Measuring Dietary Intake and Dietary Quality
- Measuring Physical Activity and Sedentary Behavior with Actigraphy
- Question and Discussion Period

9:45 a.m.-11:15 a.m.

- ADA Chief Executive Officer Remarks (Includes Livestream)
- President, Health Care & Education Address (Includes Livestream)
- Outstanding Educator in Diabetes Award Lecture (IncludesLivestream)

11:30 a.m.-12:30 p.m.

- Professional Interest Group Discussion on Foot Care (Includes Livestream)
- Professional Interest Group Discussion on Exercise Physiology — Lactate Reimagined — More than Just a Waste Product
- Professional Interest Group Discussion on Nutrition Sciences and Metabolism — Novel Methods of Dietary Assessment
- Professional Interest Group Discussion on Women's Interprofessional Network of the ADA (WIN ADA)— Amplifying Women's Voices in the Diabetes Workforce — A Panel Discussion (Includes Livestream)
**Program Advance**

**JUNE 23-26, 2023**  
**SAN DIEGO, CA / HYBRID**

---

**Question and Discussion Period**

Denice Feig, MD, MSc, FRCPC

Patients with Type 2 Diabetes Should

---

**Welcome and Introduction**

Jeffrey S. Tessem, PhD

Emerging Roles and Interactions of

---

**Question and Discussion Period**

Boris Draznin, MD, PhD

A Model for Future Clinical Diabetes

---

**Question and Discussion Period**

Ali A. Rizvi, MD

Welcome and Introduction

---

**Question and Discussion Period**

Ashley Battarbee, MD

Not Take Metformin during Pregnancy

---

**Question and Discussion Period**

Carmella Evans-Molina, MD, PhD

Beta Cells in Islet Function

---

**Question and Discussion Period**

Loretta Vileikyte, MD, PhD

Alka M. Kanaya, MD

Tze-Woei Tan, MBBS, MPH, FACS

---

**Question and Discussion Period**

Nicholas R. Galloway, BSN, RN

Davida F. Kruguer, MSN, APN-BC, BC-ADM

Optimizing Technology for Individuals with Intellectual Disability

---

**Question and Discussion Period**

Kelly West Award for Outstanding Achievement in Epidemiology Lecture (Includes Livestream)

Alka M. Kanaya, MD

---

**Question and Discussion Period**

Tom West for Award for Outstanding Achievement in Artifical Intelligence and Diabetes Foot Disease

The Future Is Now — Artificial Intelligence and Diabetes Foot Disease

---

**Question and Discussion Period**

Barbara E. Corkey, PhD

Evidence for a New Spatially and Temporally Compartmentalized Model

---

**Question and Discussion Period**

Shivani Misra, MD, PhD

Precision Medicine in Type 1 Diabetes

---

**Question and Discussion Period**

Kevan C. Herold, MD

Leveraging Accessibility Features for

---

**Question and Discussion Period**

Robert Wagner, MD

The New Normal — Perspectives on Treatment and Trials as Immunotherapies Enter the Type 1 Diabetes Clinical Landscape

(Includes Livestream)

---

**Question and Discussion Period**

Rodolfo J. Galindo, MD

Automation Neuropathy?

---

**Question and Discussion Period**

Antoinette Moran, MD

Diabetic Neuropathy

---

**Question and Discussion Period**

Mary T. Korytkowski, MD

What Should Glucose Targets Be?

---

**Question and Discussion Period**

John A. Cocco, MD

Evidence for the Canonical Model

---

**Question and Discussion Period**

Tze-Woei Tan, MBBS, MPH, FACS

Multiancestry GWAS for Glycemic Traits

---

**Question and Discussion Period**

Shivani Misra, MD, PhD

Precision Medicine in Gestational Diabetes

---

**Question and Discussion Period**

Mary T. Korytkowski, MD

What Should Glucose Targets Be?

---

**Question and Discussion Period**

Zhila Semnani-Azad, PhD

Precision Medicine in Type 2 Diabetes

---

**Question and Discussion Period**

Guido Freckmann, MD

What is the Carbohydrate–Insulin and Energy-Balance Models (Includes Livestream)
SUNDAY, JUNE 25

8:00 a.m.–9:30 a.m.

New Treatment Possibilities for Cardiovascular Residual Risk in Diabetes? (Includes Livestream)

Do Triglycerides Contribute to Residual Cardiovascular Disease Risk in Diabetes? (Includes Livestream)

Anne Tyldgaard-Hansen, MD, DMSc

ANGPTL3 vs. APOC3 as a Therapeutic Target?

Jan Boren, MD, PhD

What is the Evidence That Lipa Is Significant in Diabetes Risk Assessment?

Calvin Yean, MD, PhD

Tracking Diabetic Kidney Disease in Type 1 and Type 2 Diabetes—The Same Disease?

Structural and Molecular Differences from Kidney Biopsies in Persons with Type 1 Diabetes and Type 2 Diabetes

Vij Nair, MS

Histopathological Features of Type 1 Diabetes “Resistors” in the Kidney

Sylvia Rosas, MD, MSCE

Can We Extrapolate Findings from Type 2 Diabetes Trials to Type 1 Diabetes?

Anamir Sinravasta, MD, MPH

Program Question and Discussion Period

9:45 a.m.–11:15 a.m.

President, Medicine & Science Address (Includes Livestream)

Rodica Pop-Busui, MD, PhD

Bantering Medal for Scientific Achievement (Includes Livestream)

Matthew H. Tischop, MD

11:30 a.m.–12:30 p.m.

Professional Interest Group Discussion on Diabetes and Cardiovascular Disease—SGLT2 Inhibitors—Innovative Research to Inform Clinical Practice (Includes Livestream)

Welcome and Introduction

Kristi Reynolds, PhD, MPH, FAHA

Data—The DiCAYA Study

Kimberly Ellis, MSN, FNP-C, CDCES

Recap of Webinar Series

Michelle D. Stancil, RN, BSN, CDCCES

Tyin the Business of DMAD?

Together—Don’t Set Any Limits

Jennifer J. D’Souza, PharmD, CDCCES, BC-ADM

Kimberly Ellis, MSN, FNP-C, CDCES

Clipper F. Young, PharmD, MPH, CDCCES, BC-ADM, BCSCP

Question and Discussion Period

Professional Interest Group Discussion on Diabetes in Primary Care (Includes Livestream)

Welcome and Introduction

Rozalina G. McCoy, MD

Breaking the Cycle of Hypoglycemia—New Threats in Diabetes Prevention in the Real-World Practice

Kevin T. Miller, DO

Professional Interest Group Discussion on Diabetes in Youth (Includes Livestream)

Welcome and Introduction

Stuart A. Weinzimer, MD

Emerging Evidence on the Effects of Sleep in Young People

Sarah S. Jaser, PhD

Program Question and Discussion Period

Art of Writing a Winning Grant

Basic Science Perspective

Clinical/Translational Science Perspective

Professional Interest Group Discussion on Behavioral Markers of Diabetes Self-Management—Perspectives from Clinicians and People with Diabetes

Welcome and Introduction

Carla K. Miller, PhD

Diabetic Retinopathy Results from the TODAY Study

Recap of Webinar Series

Lisa S. Chow, MD, MS

Gibbottosi-Clug, MD, PhD

Protein-Cwchara Pharmacotherapy

Stimulated Hormone Pharmacotherapy

Clinical Implications of Nutrient-Stimulated Hormones—Nutrient-Stimulated Hormones—

FTOS

Jonathan Campbell, MD

Role for Amylin in Monotherapy and Combination Therapy

Chantal Mathieu, MD, PhD

Contribution of PYY in Combination Treatment with GLP-1

Teresa Jones, MD

Looking Towards the Future—Ongoing Stages

Qi Hei Karen Lau, MS, RDN, LDN, CDCEES

Binge-Eating Disorder and Weight Stigma

Meg Salvia, MS, RDN, CDCEES

Question and Discussion Period

It’s About Time—Eating and Exercising in Metabolic Health

Circadian Rhythms, Time-Restricted Eating, and Metabolic Health

Lisa S. Chow, MD, MS

Time-Restricted Feeding Improves Cardiometabolite Profiles

Kylie Kavanagh, DVM, MS, MPH

Circadian Rhythm and Metabolism

Adim Weijie, PhD

Acute Exercise Modifies the Hepatic Proteome and Metabolic Flux

Rajendra P. Yadav, MD

Nutrient-Stimulated Hormones—Anti-Obesity Pharmacotherapy

Game Changers (Includes Livestream)

Contribution of Gastric Inhibitory Peptide and Glucagon in Dual and Triple Agonism

Jonathan Campbell, PhD

Panel Discussion

1:30 p.m.–3:30 p.m.

Professional Interest Group Discussion on Diabetes Prevention in New Themes in Diabetes Prevention in the Real-World Practice

Sarah S. Jaser, PhD

Program Question and Discussion Period

Art of Writing a Winning Grant

Basic Science Perspective

Clinical/Translational Science Perspective

Professional Interest Group Discussion on Diabetes Self-Management Education and Support (DSMES) (Includes Livestream)

Recap of Webinar Series

Michelle D. Stancil, RN, BSN, CDCCES

Tyin the Business of DMAD?

Together—Don’t Set Any Limits

Jennifer J. D’Souza, PharmD, CDCCES, BC-ADM

Kimberly Ellis, MSN, FNP-C, CDCES

Clipper F. Young, PharmD, MPH, CDCCES, BC-ADM, BCSCP

Question and Discussion Period

Professional Interest Group Discussion on Diabetes and Cardiovascular Disease—SGLT2 Inhibitors—Innovative Research to Inform Clinical Practice (Includes Livestream)

Welcome and Introduction

Kristi Reynolds, PhD, MPH, FAHA

Data—The DiCAYA Study

Kimberly Ellis, MSN, FNP-C, CDCES

Recap of Webinar Series

Michelle D. Stancil, RN, BSN, CDCCES

Tyin the Business of DMAD?

Together—Don’t Set Any Limits

Jennifer J. D’Souza, PharmD, CDCCES, BC-ADM

Kimberly Ellis, MSN, FNP-C, CDCES

Clipper F. Young, PharmD, MPH, CDCCES, BC-ADM, BCSCP

Question and Discussion Period
3:15 p.m.-4:15 p.m.

- What’s the Verdict on Telehealth for Behavioral and Psychological Diabetes Care? (Includes Livestream)
  Telehealth increases access, fosters innovations, and achieves at least some of the clinical outcomes to in-person care. Jennifer Raymond, MD, MCR
  Somewhere and Someone Are Missing — Gaps in Telehealth Models for Psychosocial Diabetes Care Michael A. Harris, PhD
  Rebuttal Jennifer Raymond, MD, MCR
  Rebuttal Michael A. Harris, PhD

- Dual-Incretin Duel (Includes Livestream)
  How Can We Afford It? Ilir B. Hirsch, MD
  Pro — How Can We Not Afford It? Carol H. Wysham, MD, PhD
  Rebuttal Ilir B. Hirsch, MD
  Rebuttal Carol H. Wysham, MD, PhD
  Question and Discussion Period

- Aging-Related Metabolic Disease — Major Drivers and Therapeutic Strategies (Includes Livestream)
  James L. Kirkland, MD, PhD
  Question and Discussion Period

- Oral Presentations

- ePoster Theaters
  4:30 p.m.-6:00 p.m.

- Current Controversies in the Primary Prevention of Diabetes Macrovascular Complications (Includes Livestream)
  Current Controversies in the Primary Prevention of Diabetes Macrovascular Complications Michael John Wilkinson, MD
  Kari E. Watson, MD, PhD
  Heather M. Johnson, MD

- Creating a World without Visual Loss from Diabetes
  The Goal of Eliminating Blindness from Diabetic Retinal Disease S. Robert Levine, MD
  The Importance of Studying the Human Retinal Disease Patrice E. Fort, MS, PhD
  Structure-Function Connections in Human Diabetic Retinal Disease Stefka Vujosevic, MD, PhD
  Designing Clinical Trials Based on Advanced Understanding of Diabetic Retinal Disease Jennifer Sun, MD, MPH
  Question and Discussion Period

- Let’s Talk Treatment — Discussing Options for Weight and Diabetes Management
  Shared Decision Making in Counseling People with Higher Weight on Lifestyle and Behavior Changes Eileen Stellstof Myers, MPH, RDN, LDN, CEDRD, FAND
  Integration of Glucose Lowering and Weight Loss Medications in the Conversation When Counseling People with Higher Weight Richard E. Pratley, MD
  Integration of Metabolic Surgery Options in Excess Weight Care in the Conversation When Counseling People with Higher Weight Laura Andromalos, MS, RD, RN, CSWON, CDCESS
  Question and Discussion Period

- Joint ADA/ADCES Symposium — Implementing Technology into a Busy Practice — It Takes a Village! (Includes Livestream)
  Introduction
  Jane Jefrie Seley, DNP, MPH, MSN, GNP-RN, BC-ADM, CDEES, CODC
  The New Diabetes Technology Practice Competencies — Validating the Recommendations
  Alison Hughes, PhD
  Question and Discussion Period Led by Paul J. Duker, MPH, BSN and Kirsten Yeh, MS, MLS

- Time-in-Range — Where Are We Headed in 2023? (Includes Livestream)
  Time-in-Range in Clinical Trials
  Rebuttal
  Time-in-Range from a Regulatory Perspective
  Patrick Archdeacon, MD
  Time-in-Range in Clinical Decision Support
  Daniel DeSalvo, MD
  Time-in-Range from the Patient Perspective
  Kelly L. Glose, MBA
  Question and Discussion Period

- Improving Outcomes for Adolescents with Type 2 Diabetes
  Interdisciplinary Team Approach to Type 2 Diabetes Management
  Katie L. O’Sullivan, MD
  Developing Community-Based Interventions for Youth with Obesity and Diabetes
  Medical or Surgical Treatment for Youth-Onset Type 2 Diabetes
  Amy Sanghavi Shah, MD, MS

- Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes — Results from OASIS 1 and PIONEER PLUS Trials (Includes Livestream)
  Rationale for Evaluating Higher-Dose GLP-1RAs
  Vanita R. Aroda, MD
  OASIS 1 Results
  Filip K. Knop, MD, PhD
  PIONEER PLUS Trial Design and Baseline Characteristics
  Sue D. Pedersen, MD, FRCPG
  PIONEER PLUS Results
  Vanita R. Aroda, MD
  Placing OASIS 1 and PIONEER PLUS into Current Context (Independent Discussant)
  Sean Wharton, MD, PhD
  Question and Discussion Period

- The Ongoing Impact of the DCCT/EDIC Study at 40 Years
  Overview and Design of DCCT and EDIC — From Clinical Trial to Epidemiology
  The Amelioration of Microvascular Complications and Their Major Risk Factors in DCCT/EDIC
  Barbara H. Braffett, PhD
  Cardiovascular Disease in Type 1 Diabetes
  Functional Impact of Long-Standing Type 1 Diabetes — Cognition, Physical Function, Hearing, and Skeletal Health
  Catherine Martin, MS, RN
  What Can EDIC Still Contribute? Future Directions
  Rose Gubitosi-Klug, MD
  Clinical Perspective — How DCCT/EDIC Changed the Care of Type 1 Diabetes
  Bruce A. Perkins, MD, MPH
  Rodica Pop-Busui, MD, PhD
  Question and Discussion Period

- Controlling the Communicators — Cytokine-Specific Therapies to Preserve Beta-Cell Function in Type 1 Diabetes
  IL-6 in the Preservation of Beta-Cell Function
  David R. Klatzmann, MD, PhD
  Treatment of Type 1 Diabetes with IL-2
  John Todd, FMedSci, FRS
  Jabirus in the Treatment of Type 1 Diabetes
  Thomas Kay, PhD
  Ustekinumab in the Treatment of Type 1 Diabetes
  Coln Dayan, MD
  Perspective on Cytokine Specific Therapies in Type 1 Diabetes
  Massimo Gadina, PhD

- Cellular Cross Talk Regulating Insulin Action
  Spatial compartmentation of protein and metabolites
  Adam Hughes, PhD, BS
  Interorganellar Metabolic Cross Talk
  Jiandie Lin, PhD
  Spatial, Temporal, and Rigidity Regulation of Cellular Function
  Wendy Gordon, PhD
  Changing the Conversation — How PTM’s Moderate Organellar Cross Talk
  Li Qiang, PhD
  Question and Discussion Period

- How Sex Shapes Metabolism and Glucose Homeostasis
  Sex-Specific Adipose Development
  Matthew S. Rodeheffer, PhD
  Estrogen Reawakening of the Neural Circuitry Controlling Energy Balance
  Yong Xu, PhD
  Hormonal Control Over Energy Balance
  Franck Mauvais-Jarvis, MD, PhD
  Liver Lipid Metabolism Interacting with Hormones to Regulate Sex Differences in Immunity
  Jorn Nikkanen, PhD
  Question and Discussion Period

- Chrononutrition for the Prevention and Treatment of Diabetes
  Impact of Time-Restricted Eating on Cardiometabolic Health — The Healthy Heroes Trial
  Emily Manoogian, PhD
  Feasibility of Time-Restricted Eating for Prevention and Treatment of Type 2 Diabetes
  Jonas Salling Quist, MSc, PhD
  Time-Restricted Eating to Prevent and Treat Metabolic Disease — From Rodents to Humans
  Satchidananda Panda, PhD

- Beta-Cell Identity from Prenatal Life to Death
  Fetal Beta Cells
  Raphael Scharfmann, PhD
  Postnatal Beta Cells
  Mark Hussing, PhD
  Beta Cell Aging
  Rafael Arrojo e Drigo, PhD

- Oral Presentations
Monday, June 26

8:00 a.m.–9:30 a.m.

**SGLT2 and GLP-1R in Cardiovascular Disease**—An Update for Clinical Practice in 2023 (Includes Livestream)

SGLT2/GLP-1R in Cardiovascular Disease—Overview
Darren K. McGuire, MD, MHS
gSGLT2 in Heart Failure—An Update
Gowri Gopalan, MD, BCPS, BC-ADM
SGLT2/GLP-1R in Atherosclerotic Cardiovascular Disease—An Update
Pam R. Taub, MD, FACC
SGLT2/GLP-1R in Combination with Cardiovascular Disease Medications—Safety, Efficacy, Benefit, Order
Question and Discussion Period

**Empowering the Acute Care Team to Optimize Diabetes Care and Education**
The Art and Science of Dosing Insulin in Acute Care
Felicia Mendelson, MD
Creative Diabetes Orders—If They Can Click on It, They’ll Order It
Jessica Zhao, PharmD, BCPS, BC-ADM
The Good, the Bad, and the Ugly—A Case Study
Jessica Odom, PharmD, BCPS, BC-ADM
SGLT2/GLP-1R in Combination with Aging, Body Composition, and Cardiovascular Disease—An Update
Priya Pralhalad, MD, PhD
Looking through the ADA Lenses—2023 ADA Guidelines for Pediatrics
John B. Buse, MD, PhD
Translational
Anath Shalev, MD
Basic
Question and Discussion Period

**ADA Symposium—Major Advances and Discoveries in Diabetes**—The Year in Review (Includes Livestream)
Clinical
John B. Buse, MD, PhD
Translational
Anath Shalev, MD
Basic
Question and Discussion Period

**NIDDK Early Career Investigator Symposium—Behavioral and Physiological Adaptations to Optimize Glucose Control with Technology**—What Is Needed to Improve Outcomes and to Overcome Access and Adoption Barriers
Welcome Remarks from the NIDDK Director
What Is Needed to Improve Outcomes?
More Physiological and Long-Lasting Delivery of Hormone Replacement in Diabetes
Eric A. Appel, PhD
What Is Needed to Improve Outcomes?
Technological, Physiological, and Behavioral Adaptations Needed for More Automated Systems
Laya Etkinshaour, PhD
Strategies to Improve Usability and Overcome Access and Adoption Barriers
Optimizing Diabetes Device Use in Early Adolescents Living with Type 1 Diabetes
Dongjin Guan, PhD
Understanding Liver Functions and Diseases by scRNAseq
Ashley Webb, PhD
A Single-Cell Atlas of White Adipose Tissue
Evan Rosen, MD, PhD
New Insight on CNS Regulation of Energy Balance Using scRNAseq Approach
Giles Yeo, PhD
Question and Discussion Period

**All the Omics—What Do They Tell Us about Diabetes?**
Integrated Single Nucleus Omics across Pancreas Development
Julie B. Sneddon, PhD
Integrated and Diverse Omics and Data Science
mRNA and CHAO-seq in Human Tissues and Organoids
Andrés García, PhD
Cotransplantation of Other Cell Types to Inflame Engraftment
Qing Yang, PhD
Monitoring of Patients Post-Transplant Norma Sue Keryon, PhD
Question and Discussion Period

**Metabolic Adaptation to Weight Loss in Humans**
Metabolic Flexibility to Weight Loss
Paul MacLean, PhD
The Role of Adaptive Thermogenesis in Weight Loss and Regain
Abdul G. Dullo, PhD
Adaptations to Changes in Weight
Anthony W. Ferrante, MD, PhD
Question and Discussion Period

**Teaching Diabetes Champions to Care for the Patient**
Guillermo E. Umpierrez, MD, CDCES
Creative Diabetes Orders—If They Can
Felicia Mendelsohn, MD
Acute Care Education
Danielle Schmitt, PhD
Understanding Liver Functions and Metabolism
Dongyin Guan, PhD
New Insight on Tumor Necrosis Factor (TNF) Receptor Signaling and Beta-Cell Death
Andrew T. Templin, PhD
9:45 a.m.–11:15 a.m.

**National Scientific & Health Care Achievement Award Presentation (Includes Livestream)**
Outstanding Scientific Achievement Award Lecture (Includes Livestream)
Carmela Evans-Molina, MD, PhD
11:30 a.m.–1:30 p.m.

**Professional Interest Group Discussion on Public Health and Epidemiology—Have We Succeeded in Type 2 Diabetes Primary Prevention? A Debate**
Welcome and Introduction
Noël C. Baren, MD, PhD, MPH
Have We Succeeded in Type 2 Diabetes Primary Prevention? Pros
Pablo Aschner, MD, MSc
Have We Succeeded in Type 2 Diabetes Primary Prevention? Cons
Julio Echouffo Tcheugui, MD, PhD
Question and Discussion Period

**Professional Interest Group Discussion on Public Health and Epidemiology—What Is Needed to Improve Outcomes?**
Welcome and Introduction
Viral Shah, MD
A Registry Study of Hybrid Closed-Loop Systems during Pregnancy—Endocrine Perspective
Genevieve O’Malley, MD
A Registry Study of Hybrid Closed-Loop Systems during Pregnancy—Maternal and Fetal Medicine Perspective
Celeste P. Durrwald, MD
Question and Discussion Period

**Strategies to Improve the Use of SGLT2 Inhibitors and GLP-1RAs in Primary Care**
Mary K. Rhee, MD
Approaches to Effective Screening for Prediabetes and Diabetes
Shohineh Samaa, MD, MPH, FRCP
4:00 p.m.–5:30 p.m.

**Cultivating Provider Resiliency and Preventing Burnout (Includes Livestream)**
Welcome and Introduction
Robert A. Gabbay, MD, PhD
Providing Cultivation Resilience Addressing Provider Burnout
J. Robinson Singleton, MD
5:45 p.m.–7:15 p.m.

**The Role of Adaptive Thermogenesis in Weight Loss**
Paul MacLean, PhD
The Role of Adaptive Thermogenesis in Weight Loss and Regain
Abdul G. Dullo, PhD
Adaptations to Changes in Weight
Anthony W. Ferrante, MD, PhD
Question and Discussion Period

**Strategies to Improve the Use of SGLT2 Inhibitors and GLP-1RAs in Primary Care**
Mary K. Rhee, MD
Approaches to Effective Screening for Prediabetes and Diabetes
Shohineh Samaa, MD, MPH, FRCP
4:00 p.m.–5:30 p.m.

**Cultivating Provider Resiliency and Preventing Burnout (Includes Livestream)**
Welcome and Introduction
Robert A. Gabbay, MD, PhD
Providing Cultivation Resilience Addressing Provider Burnout
J. Robinson Singleton, MD
5:45 p.m.–7:15 p.m.

**The Role of Adaptive Thermogenesis in Weight Loss**
Paul MacLean, PhD
The Role of Adaptive Thermogenesis in Weight Loss and Regain
Abdul G. Dullo, PhD
Adaptations to Changes in Weight
Anthony W. Ferrante, MD, PhD
Question and Discussion Period

**Strategies to Improve the Use of SGLT2 Inhibitors and GLP-1RAs in Primary Care**
Mary K. Rhee, MD
Approaches to Effective Screening for Prediabetes and Diabetes
Shohineh Samaa, MD, MPH, FRCP
4:00 p.m.–5:30 p.m.

**Cultivating Provider Resiliency and Preventing Burnout (Includes Livestream)**
Welcome and Introduction
Robert A. Gabbay, MD, PhD
Providing Cultivation Resilience Addressing Provider Burnout
J. Robinson Singleton, MD
5:45 p.m.–7:15 p.m.

**The Role of Adaptive Thermogenesis in Weight Loss**
Paul MacLean, PhD
The Role of Adaptive Thermogenesis in Weight Loss and Regain
Abdul G. Dullo, PhD
Adaptations to Changes in Weight
Anthony W. Ferrante, MD, PhD
Question and Discussion Period
**ADVANCE PROGRAM**

### Exercise as Medicine — Physical Activity for Preventing and Managing Diabetes Complications
Prevention of Microvascular Complications in Prediabetes (ePRIDECE) Study
Jaakko Tuomilehto, MD, PhD
Can You Feel It? High Intensity Training to Improve Hyposglycemia Unawareness
Rory J. McCrimmon, MD
An Ounce of Prevention — Exercise and Sedentary Behavior in Youth with Diabetes
Kimber M. Simmons, MD, MS

### ADA Education Recognition Program (ERP) — Impact in Pregnancy — MOMs in Control of Diabetes of South Carolina
MOMs in Control — Team-Based Approach
Daniel N. Pasko, MD
MOMs in Control — ERP Expansion
Jessica Odom, PharmD, BCPS, BC-ADM
MOMs in Control — Day-to-Day Services
Hannah White, MS, RD, CDEs
MOMs in Control — Medication and Technology Management
Jessica Odom, PharmD, BCPS, BC-ADM

### Extending Our Reach — Using Technology and Clinical Collaborations to Improve Outcomes
Project ECHO (Extension for Community Health Outcomes) Diabetes
Matthew F. Bouchonville II, MD
E-Consults and Professional Continuous Glucose Monitoring with Recommendations
Kathryn Fantasia, MD
The Cardiology, Renal, and Exercise Collaborations to Improve Outcomes
Saria Hassan, MD, MPH

### Overcoming Barriers to Diabetes Technology
Overcoming Barriers to Technology in Primary Care
Thomas W. Martens, MD
Psychological Considerations in Technology Adoption
Kimberly A. Driscoll, PhD
The EHR and Data Integration — The Present and the Future, and in What Settings?
Peter A. Senior, MBBS, PhD
Current State of Stem-Cell-Based Islet Therapies in Patients — Progress and Challenges
Eelco J.P. de Koning, MD, PhD

### Clinical Cell Therapy for Diabetes
Introduction — Clinical Islet Transplantation — Where Are We Now?
David A. Berdal, MD
Islet Auto-Transplant — Lessons Learned for Cell Therapy in Diabetes
Miera Bellin, MD
Is There a Role for Cadaveric Islet Transplantation at Academic Centers in the Future, and in What Settings?
Peter A. Senior, MBBS, PhD

### Exercise and Metabolic Health — Insight from Animal Studies
Lysozyme Acetylation as a Critical Regulator of Glucose Uptake during Exercise
Simon Schenk, PhD
Cellular and Synaptic Reorganization of Hypothalamic Neurons after Exercise
Kevin Williams, PhD
Energy Metabolism in Skeletal Muscle and Exercise Capacity
Xing Xing Kong, MD
Microbiome Regulation of Exercise and Exercise Capacity
Christoph A. Thais, BS, MD, PhD

### Oral Presentations

### 3:15 p.m.-4:15 p.m.

### Beyond Antihyperglycemic and Antipathogenic Agents for Diabetic Kidney Disease (Includes Livestream)
Are We Following the Guidelines and Using the Newer Therapies to Protect against Diabetic Kidney Disease?
Christine Limonte, MD
Future Therapies Targeting Mitochondrial Dysfunction and Oxidative Stress to Mitigate Diabetic Kidney Disease (Inntracell NAD+, JAK-STAT, TGF-beta)
Ashish Verma, MD
What about Children and Adolescents with Diabetes?
Kalie L. Tommerdahl, MD

### Doc, Is My GLP-1 Med Making My Sight Worse? New Considerations in Management of Diabetic Retinopathy (Includes Livestream)
Novel Diabetes Therapies (GLP-1, SGLT2, DPP-4s) and Diabetic Retinopathy
Arun J. Sanyal, MD
New Therapies for Diabetic Retinopathy — How Do They Compare with What We Already Have?
Quan Dong Nguyen, MD, MSc

### Early Diagnosis of Diabetes Cardiomyopathy (DiCm) — What Can Be Done?
Cross-Sectional Analysis of a Large Cohort of Patients with DiCm Enrolled in a Longitudinal Study — The Baseline Results of the ARSIE-HF Trial
Elizabeth Rideout, PhD, BSc
Diagnosis of Diabetes Cardiomyopathy Based on Circulating Marker of Disease
James L. Januzi, MD
Molecular Mechanisms Leading to Diabetic Cardiomyopathy
Lim Kua, MD

### Updates in Diabetes and Fasting Diabetes and Ramadan Fast — For a Safer Intermittent Fasting and Diabetes Question and Discussion Period

### Shared Decision-Making Either Isn’t Practiced or Isn’t Working
Pro — Shared Decision-Making Has Unintended Negative Consequences
Con — Shared Decision-Making Is the Cornerstone for Patient-Centered Care Question and Discussion Period

### Is Metabolic Surgery or Lifestyle/ Medical Management of Type 2 Diabetes Optimal for Long-Term Health? Long-Term Outcomes of the ARMDMS-T2D Randomized Trial after 7–15 Years of Follow-Up (Includes Livestream)
The Case for an ACT of Metabolic Surgery and Type 2 Diabetes
John P. Kirwan, MSc, PhD, FACSIM
Study Design of the ARMDMS-T2D Randomized Trial
Mary-Elizabeth Patti, MD
Long-Term HA1c Outcomes and Diabetes Remission at 7–15 Years
Anita Courcoulas, MD, MPH
Implications for Clinical Management of Type 2 Diabetes
Robert H. Eckel, MD

### Standardization of Person-Reported Outcomes (PROs) — A Consensus Statement
Introduction to the Consensus Statement and What It Will Achieve
David G. Marrero, PhD
Core Psychosocial Domains and the Underpinning Science of PROs
Katharine D. Barnard-Kelly, PhD
What to Look for in a PRO Measure
Jessica Pierce, PhD
PROs from a Person with Diabetes Perspective
Jennifer Sher, MD, PhD

### Comparing Beta-Cell Replacement vs. Artificial Pancreas — Smart Insulin with a Focus on New Innovations — Untested Technologies (Includes Livestream)
For Beta Cell Replacement
Michael R. Rickels, MD, MS
For Emerging Innovations
Bruce A. Buckingham, MD
Rebutil
Michael R. Rickels, MD, MS
Rebutil
Bruce A. Buckingham, MD

### Oral Presentations